{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:41:42Z","timestamp":1785210102641,"version":"3.55.0"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This review examines current developments and controversies in the multimodal management of oesophageal cancer, with an emphasis on surgical dilemmas and outcomes from the surgeon's perspective.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Despite the advancement of oncological neoadjuvant treatments, there is still no consensus on what regimen is superior. The majority of patients may still fail to respond to neoadjuvant therapy and suffer potential harm without any survival advantage as a result. In patients who do not respond, adjuvant therapy is still often recommended after surgery despite any evidence for its benefit. We examine the implications of different regimens and treatment approaches for both squamous cell cancer and adenocarcinoma of the oesophagus.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The efficacy of neoadjuvant treatment is highly variable and likely relates to variability of tumour biology. Ongoing work to identify responders, or optimize treatment on an individual patient, should increase the efficacy of multimodal therapy and improve patient outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cco.0000000000000751","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T10:01:19Z","timestamp":1620640879000},"page":"353-361","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Thinking through the multimodal treatment of localized oesophageal cancer: the point of view of the surgeon"],"prefix":"10.1097","volume":"33","author":[{"given":"Philip H.","family":"Pucher","sequence":"first","affiliation":[{"name":"Department of Surgery, Guy's and St Thomas\u2019 NHS Foundation Trust, London"},{"name":"Department of Surgery, Portsmouth University Hospitals NHS Trust, Portsmouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas P.L.","family":"Wijnhoven","sequence":"additional","affiliation":[{"name":"Department of Surgery, Erasmus MC-Erasmus University Medical Centre, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Underwood","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, Faculty of Medicine, University of Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Department of Surgery, National Oesophageal and Gastric Center, St. James's Hospital and Trinity College, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Davies","sequence":"additional","affiliation":[{"name":"Department of Surgery, Guy's and St Thomas\u2019 NHS Foundation Trust, London"},{"name":"King's College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1200\/JCO.2009.22.2083","article-title":"Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer","volume":"27","author":"Allum","year":"2009","journal-title":"J Clin Oncol"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM199707173370304","article-title":"Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus","volume":"337","author":"Bosset","year":"1997","journal-title":"N Engl J Med"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/bjs.8968","article-title":"Recurrence pattern in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer","volume":"100","author":"van Hagen","year":"2013","journal-title":"Br J Surg"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/jso.25089","article-title":"Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus","volume":"117","author":"Visser","year":"2018","journal-title":"J Surg Oncol"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/annonc\/mdw560","article-title":"Multimodality treatment for esophageal adenocarcinoma: multicenter propensity-score matched study","volume":"28","author":"Markar","year":"2017","journal-title":"Ann Oncol"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.ejso.2020.06.038","article-title":"Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: inverse propensity score weighted analysis","volume":"46","author":"Pucher","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejca.2017.04.027","article-title":"Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of a controlled randomised trial","volume":"81","author":"Stahl","year":"2017","journal-title":"Eur J Cancer"},{"key":"R13-20250526","doi-asserted-by":"crossref","DOI":"10.1093\/dote\/doy078","article-title":"Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial","volume":"32","author":"von Dobeln","year":"2019","journal-title":"Dis Esophagus"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.2013.51.2186","article-title":"Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials","volume":"32","author":"Oppedijk","year":"2014","journal-title":"J Clin Oncol"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1186\/s12885-016-2564-y","article-title":"ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286)","volume":"16","author":"Hoeppner","year":"2016","journal-title":"BMC Cancer"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12885-017-3386-2","article-title":"ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS)","volume":"17","author":"Reynolds","year":"2017","journal-title":"BMC Cancer"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/bjs.10627","article-title":"Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma","volume":"104","author":"Noble","year":"2017","journal-title":"Br J Surg"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s11605-018-4007-3","article-title":"Low- vs. high-dose neoadjuvant radiation in trimodality treatment of locally advanced esophageal cancer","volume":"23","author":"Ji","year":"2019","journal-title":"J Gastrointest Surg"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/bjs.10900","article-title":"Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma","volume":"105","author":"Davies","year":"2018","journal-title":"Br J Surg"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/bja\/aeu318","article-title":"Effect of prehabilitation on objectively measured physical fitness after neoadjuvant treatment in preoperative rectal cancer patients: a blinded interventional pilot study","volume":"114","author":"West","year":"2015","journal-title":"Br J Anaesth"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1007\/s00330-014-3110-4","article-title":"Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer","volume":"24","author":"Yip","year":"2014","journal-title":"Eur Radiol"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.ejso.2014.03.021","article-title":"The effects of neoadjuvant chemoradiotherapy on physical fitness and morbidity in rectal cancer surgery patients","volume":"40","author":"West","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1245\/s10434-018-6554-y","article-title":"Outcome of patients treated within and outside a randomized clinical trial on neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: extrapolation of a randomized clinical trial (CROSS)","volume":"25","author":"Toxopeus","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s11605-020-04704-5","article-title":"Real-world scenario: CROSS regimen as preoperative therapy for oesophageal squamous cell carcinoma","volume":"24","author":"Wong","year":"2020","journal-title":"J Gastrointest Surg"},{"key":"R25-20250526","first-page":"CD011498","article-title":"Nonsurgical versus surgical treatment for oesophageal cancer","volume":"3","author":"Best","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.2005.00.034","article-title":"Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus","volume":"23","author":"Stahl","year":"2005","journal-title":"J Clin Oncol"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2005.04.7118","article-title":"Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102","volume":"25","author":"Bedenne","year":"2007","journal-title":"J Clin Oncol"},{"key":"R28-20250526","article-title":"Definitive chemoradiotherapy compared to neoadjuvant chemoradiotherapy with esophagectomy for locoregional esophageal cancer: national population-based cohort study","author":"Kamarajah","year":"2020","journal-title":"Ann Surg"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"2710.e3","DOI":"10.1016\/j.jtcvs.2018.01.086","article-title":"Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma","volume":"155","author":"Barbetta","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/bjs.11004","article-title":"Survival after neoadjuvant chemoradiotherapy and oesophagectomy versus definitive chemoradiotherapy for patients with oesophageal squamous cell carcinoma","volume":"106","author":"Wang","year":"2019","journal-title":"Br J Surg"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/bjc.2014.313","article-title":"Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer","volume":"111","author":"Blazeby","year":"2014","journal-title":"Br J Cancer"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s11605-019-04141-z","article-title":"Influence of neoadjuvant radiation dose on patients undergoing esophagectomy and survival in locally advanced esophageal cancer","volume":"23","author":"Ising","year":"2019","journal-title":"J Gastrointest Surg"},{"issue":"(4 Suppl)","key":"R33-20250526","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1200\/JCO.2020.38.4_suppl.281","article-title":"A randomized controlled phase III multicenter study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer: ARTDECO study","volume":"38","author":"Hulshof","year":"2020","journal-title":"J Clin Oncology"},{"issue":"(15 Suppl)","key":"R34-20250526","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2017.35.15_suppl.4037","article-title":"Exclusive chemoradiotherapy with or without dose escalation in locally advanced esophageal carcinoma: the CONCORDE study (PRODIGE 26)","volume":"35","author":"Crehange","year":"2017","journal-title":"J Clin Oncol"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jtho.2016.10.002","article-title":"Final results of NRG Oncology RTOG 0246: an organ-preserving selective resection strategy in esophageal cancer patients treated with definitive chemoradiation","volume":"12","author":"Swisher","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.ejcts.2008.01.056","article-title":"Indications and outcome of salvage surgery for oesophageal cancer","volume":"33","author":"D\u2019Journo","year":"2008","journal-title":"Eur J Cardiothorac Surg"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ejso.2018.11.002","article-title":"A meta-analysis on salvage surgery as a potentially curative procedure in patients with isolated local recurrent or persistent esophageal cancer after chemoradiotherapy","volume":"45","author":"Faiz","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1200\/JCO.2014.59.9092","article-title":"Salvage surgery after chemoradiotherapy in the management of esophageal cancer: is it a viable therapeutic option?","volume":"33","author":"Markar","year":"2015","journal-title":"J Clin Oncol"},{"key":"R39-20250526","doi-asserted-by":"crossref","DOI":"10.1093\/dote\/doaa085","article-title":"Effect of anastomotic leaks on long-term survival after oesophagectomy for oesophageal cancer: systematic review and meta-analysis","volume":"34","author":"Gujjuri","year":"2021","journal-title":"Dis Esophagus"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/bjs.9615","article-title":"Meta-analysis of the effect of postoperative in-hospital morbidity on long-term patient survival","volume":"101","author":"Pucher","year":"2014","journal-title":"Br J Surg"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"18022","DOI":"10.3748\/wjg.v20.i47.18022","article-title":"Three-field vs two-field lymph node dissection for esophageal cancer: a meta-analysis","volume":"20","author":"Ma","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S1470-2045(18)30201-8","article-title":"Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study","volume":"19","author":"Noordman","year":"2018","journal-title":"Lancet Oncol"},{"key":"R43-20250526","article-title":"Active surveillance versus immediate surgery in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal cancer: a multicenter propensity matched study","author":"van der Wilk","year":"2019","journal-title":"Ann Surg"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1016\/j.ejso.2020.11.211","article-title":"Chemoradiotherapy followed by active surveillance versus surgery for esophageal cancer: a systematic review and individual patient data meta-analysis","volume":"47","author":"Van Der Wilk","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000341353","article-title":"Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation","volume":"83","author":"Taketa","year":"2012","journal-title":"Oncology"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1002\/bjs.10897","article-title":"Patients\u2019 preferences for treatment after neoadjuvant chemoradiotherapy for oesophageal cancer","volume":"105","author":"Noordman","year":"2018","journal-title":"Br J Surg"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12885-018-4034-1","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial","volume":"18","author":"Noordman","year":"2018","journal-title":"BMC Cancer"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1097\/SLA.0000000000001825","article-title":"The impact of adjuvant postoperative radiation therapy and chemotherapy on survival after esophagectomy for esophageal carcinoma","volume":"265","author":"Wong","year":"2017","journal-title":"Ann Surg"},{"key":"R50-20250526","first-page":"1801","article-title":"Adjuvant therapy following oesophagectomy for adenocarcinoma in patients with a positive resection margin","volume":"107","author":"Bott","year":"2020","journal-title":"Br J Surg"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamaoncol.2017.2805","article-title":"Adjuvant chemotherapy vs postoperative observation following preoperative chemoradiotherapy and resection in gastroesophageal cancer: a propensity score-matched analysis","volume":"4","author":"Mokdad","year":"2018","journal-title":"JAMA Oncol"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1470-2045(17)30043-8","article-title":"Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial","volume":"18","author":"Cunningham","year":"2017","journal-title":"Lancet Oncol"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/bjs.11184","article-title":"Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro-oesophageal junction","volume":"106","author":"Allum","year":"2019","journal-title":"Br J Surg"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"771","DOI":"10.21037\/jgo.2016.08.06","article-title":"The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1","volume":"7","author":"Jin","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1186\/s12885-019-5675-4","article-title":"EORTC-1203-GITCG - the \u2018INNOVATION\u2019-trial: effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group","volume":"19","author":"Wagner","year":"2019","journal-title":"BMC Cancer"},{"key":"R57-20250526","article-title":"EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers","author":"Smyth","year":"2020","journal-title":"Gut"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.athoracsur.2014.04.099","article-title":"Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation","volume":"98","author":"Patel","year":"2014","journal-title":"Ann Thorac Surg"},{"key":"R59-20250526","doi-asserted-by":"crossref","first-page":"102024","DOI":"10.1016\/j.ctrv.2020.102024","article-title":"MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma","volume":"86","author":"van Velzen","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"e1921290","DOI":"10.1001\/jamanetworkopen.2019.21290","article-title":"Evaluation of the association of perioperative UGT1A1 genotype-dosed gFOLFIRINOX with margin-negative resection rates and pathologic response grades among patients with locally advanced gastroesophageal adenocarcinoma: a phase 2 clinical trial","volume":"3","author":"Catenacci","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R62-20250526","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1200\/JCO.2006.06.7801","article-title":"Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction","volume":"24","author":"Ott","year":"2006","journal-title":"J Clin Oncol"},{"key":"R63-20250526","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1470-2045(07)70244-9","article-title":"PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial","volume":"8","author":"Lordick","year":"2007","journal-title":"Lancet Oncol"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2967\/jnumed.110.085803","article-title":"(18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial","volume":"52","author":"zum Buschenfelde","year":"2011","journal-title":"J Nucl Med"},{"issue":"(15 Suppl)","key":"R65-20250526","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2018.36.15_suppl.4012","article-title":"Survival outcomes from CALGB 80803 (Alliance): a randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer","volume":"36","author":"Goodman","year":"2018","journal-title":"J ClinOncol"},{"key":"R66-20250526","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jtho.2018.10.152","article-title":"Positron-emission tomography scan-directed chemoradiation for esophageal squamous cell carcinoma: no benefit for a change in chemotherapy in positron-emission tomography nonresponders","volume":"14","author":"Greally","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R67-20250526","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.3748\/wjg.v26.i35.5256","article-title":"Artificial intelligence-assisted esophageal cancer management: now and future","volume":"26","author":"Zhang","year":"2020","journal-title":"World J Gastroenterol"},{"key":"R68-20250526","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2217\/pgs.09.137","article-title":"TaqMan low-density arrays and analysis by artificial neuronal networks predict response to neoadjuvant chemoradiation in esophageal cancer","volume":"11","author":"Warnecke-Eberz","year":"2010","journal-title":"Pharmacogenomics"},{"key":"R69-20250526","doi-asserted-by":"crossref","first-page":"e0137036","DOI":"10.1371\/journal.pone.0137036","article-title":"Predicting response to neoadjuvant chemotherapy with PET imaging using convolutional neural networks","volume":"10","author":"Ypsilantis","year":"2015","journal-title":"PLoS One"},{"key":"R70-20250526","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1002\/ctm2.110","article-title":"Predicting treatment response to neoadjuvant chemoradiotherapy in local advanced rectal cancer by biopsy digital pathology image features","volume":"10","author":"Zhang","year":"2020","journal-title":"Clin Transl Med"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000751","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T23:09:22Z","timestamp":1748300962000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000751","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,6]]}}}